Takeda Pharmaceutical Co Ltd
TSE:4502
Takeda Pharmaceutical Co Ltd
Cost of Revenue
Takeda Pharmaceutical Co Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Cost of Revenue
-¥1.4T
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-11%
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Cost of Revenue
-¥416.7B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-1%
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Cost of Revenue
-¥611.2B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
|
Eisai Co Ltd
TSE:4523
|
Cost of Revenue
-¥157.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
2%
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Cost of Revenue
-¥413.3B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-8%
|
|
Astellas Pharma Inc
TSE:4503
|
Cost of Revenue
-¥350.5B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
See Also
What is Takeda Pharmaceutical Co Ltd's Cost of Revenue?
Cost of Revenue
-1.4T
JPY
Based on the financial report for Dec 31, 2023, Takeda Pharmaceutical Co Ltd's Cost of Revenue amounts to -1.4T JPY.
What is Takeda Pharmaceutical Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-11%
Over the last year, the Cost of Revenue growth was -9%. The average annual Cost of Revenue growth rates for Takeda Pharmaceutical Co Ltd have been -11% over the past three years , -23% over the past five years , and -11% over the past ten years .